Novel LKB1-AMPK Activator for Therapeutic Use in Polycystic Kidney Disease
University of Kansas, KS, United States
The invention consists of a novel compound and method for treating Polycystic Kidney Disease utilizing a novel liver kinase B1 (LKB1) activator to stimulate AMP-activated protein kinase (AMPK), leading to inhibition of mTOR-mediated cellular proliferation and chloride-dependent fluid secretion, key components of cyst growth.
Primary Application Area: Pharmaceuticals & Personal Care
Technology Development Status: Prototype
Technology Readiness Level: TRL 4
FIGURES OF MERIT
Value Proposition: Unique composition of matter patent application.
Organization Type: Academic/Gov Lab
Showcase Booth #: 13M
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date:
Primary Sources of Funding: University
Looking for: Both Funding and Development Partners